Elicera Therapeutics AB (publ) (STO: ELIC)
Sweden
· Delayed Price · Currency is SEK 1.750
+0.030 (1.74%)
Dec 27, 2024, 5:24 PM CET
Elicera Therapeutics AB Income Statement
Financials in millions SEK. Fiscal year is January - December.
Millions SEK. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | 2018 - 2014 |
|---|---|---|---|---|---|---|---|
Period Ending | Sep '24 Sep 30, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | Dec '19 Dec 31, 2019 | 2018 - 2014 |
| Other Revenue | 4.29 | 11.23 | 1.28 | 0 | - | - | Upgrade
|
| Revenue | 4.29 | 11.23 | 1.28 | 0 | - | - | Upgrade
|
| Revenue Growth (YoY) | -63.47% | 777.23% | 217987.39% | - | - | - | Upgrade
|
| Gross Profit | 4.29 | 11.23 | 1.28 | 0 | - | - | Upgrade
|
| Selling, General & Admin | 23.46 | 28.31 | 20.63 | 13.11 | 2.82 | 0.19 | Upgrade
|
| Operating Expenses | 23.47 | 28.33 | 20.64 | 13.12 | 2.83 | 0.19 | Upgrade
|
| Operating Income | -19.19 | -17.1 | -19.36 | -13.12 | -2.83 | -0.19 | Upgrade
|
| Interest Expense | -0.05 | -0.08 | -0.13 | -0 | - | - | Upgrade
|
| Interest & Investment Income | 0.98 | 0.77 | 0.05 | - | - | 0 | Upgrade
|
| Other Non Operating Income (Expenses) | - | - | - | 0 | - | - | Upgrade
|
| EBT Excluding Unusual Items | -18.26 | -16.4 | -19.44 | -13.12 | -2.83 | -0.19 | Upgrade
|
| Gain (Loss) on Sale of Investments | - | - | - | - | 0.01 | - | Upgrade
|
| Pretax Income | -18.26 | -16.4 | -19.44 | -13.12 | -2.82 | -0.19 | Upgrade
|
| Net Income | -18.26 | -16.4 | -19.44 | -13.12 | -2.82 | -0.19 | Upgrade
|
| Net Income to Common | -18.26 | -16.4 | -19.44 | -13.12 | -2.82 | -0.19 | Upgrade
|
| Shares Outstanding (Basic) | 28 | 20 | 20 | 16 | 12 | 12 | Upgrade
|
| Shares Outstanding (Diluted) | 28 | 20 | 20 | 16 | 12 | 12 | Upgrade
|
| Shares Change (YoY) | 39.67% | -0.27% | 23.97% | 32.98% | - | - | Upgrade
|
| EPS (Basic) | -0.66 | -0.83 | -0.98 | -0.82 | -0.23 | -0.02 | Upgrade
|
| EPS (Diluted) | -0.66 | -0.83 | -0.98 | -0.82 | -0.23 | -0.02 | Upgrade
|
| Free Cash Flow | -15.73 | -14.92 | -8.57 | -14.29 | -0.91 | -0.24 | Upgrade
|
| Free Cash Flow Per Share | -0.57 | -0.75 | -0.43 | -0.89 | -0.08 | -0.02 | Upgrade
|
| Gross Margin | 100.00% | 100.00% | 100.00% | 100.00% | - | - | Upgrade
|
| Operating Margin | -447.76% | -152.24% | -1512.51% | -2234986.20% | - | - | Upgrade
|
| Profit Margin | -426.04% | -146.02% | -1518.44% | -2235169.17% | - | - | Upgrade
|
| Free Cash Flow Margin | -367.04% | -132.88% | -669.50% | -2434940.72% | - | - | Upgrade
|
| EBITDA | -19.18 | -17.08 | -19.35 | -13.11 | -2.82 | - | Upgrade
|
| EBITDA Margin | - | -152.13% | - | - | - | - | Upgrade
|
| D&A For EBITDA | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | - | Upgrade
|
| EBIT | -19.19 | -17.1 | -19.36 | -13.12 | -2.83 | -0.19 | Upgrade
|
| EBIT Margin | - | -152.24% | - | - | - | - | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.